Showing 3571-3580 of 7034 results for "".
- Autoimmune Skin Diseases Linked to Better Cancer Survival: Studyhttps://practicaldermatology.com/news/autoimmune-skin-diseases-linked-to-better-cancer-survival-study/2475516/Patients with autoimmune skin diseases (ASDs) who undergo cancer treatment may experience improved survival outcomes compared to those without ASDs, a new population-based study from Taiwan suggests. Using data derived from Ta
- Biosimilar STEQEYMA Now Approved for All Ustekinumab Dosage Forms, Strengthshttps://practicaldermatology.com/news/Biosimilar-STEQEYMA-Now-Approved-All-Ustekinumab-Dosage-Forms-Strengths/2475172/The US Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, according to a press release from Celltrion, Inc. The additional pre
- New IL-13/IL-31R Bispecific Antibody Data Presented at EAACIhttps://practicaldermatology.com/news/New-IL-13-IL-31R-Bispecific-Antibody-Data-Presented-EAACI/2475170/A new IL-13/IL-31R bispecific antibody demonstrated ability to simultaneously suppress the inflammatory and pruritogenic pathways in atopic dermatitis (AD), according to preclinical study data presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, S
- Bimekizumab 3-Year Data Shows Lasting Efficacy, Control of Inflammation for PsA, axSpAhttps://practicaldermatology.com/news/Bimekizumab-3-Year-Data-Shows-Lasting-Efficacy-Control-Inflammation-PsA-axSpA/2475126/Bimekizumab (BIMZELX®) demonstrated sustained control of inflammation and deep efficacy in patients living with psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), according to new 3-year data from phase 3 trials and open-label extensions in adults with active PsA and active axS
- Study: Belly Fat More Predictive of Psoriasis Than Overall Body Fathttps://practicaldermatology.com/news/study-belly-fat-more-predictive-of-psoriasis-than-overall-body-fat/2475108/Central adiposity—particularly abdominal fat—is more strongly linked to psoriasis risk than overall body fat, according to a new analysis published in the Journal of Investigative Dermatology.
- Study: Lifileucel Shows Sustained Benefit in Advanced Melanoma Over 5 Yearshttps://practicaldermatology.com/news/lifileucel-shows-sustained-benefit-in-advanced-melanoma-over-5-years/2475031/Lifileucel showed sustained benefit and safety in a 5-year follow-up analysis of the phase II C-144-01 study in patients with advanced melanoma, according to a new study in the Journal of Clinical Oncology. Patien
- Huma Announces AI Tool to Automate Clinical Notes and Billinghttps://practicaldermatology.com/news/huma-announces-ai-tool-to-automate-clinical-notes-and-billing/2475018/Huma Therapeutics announced the launch Hi Scribe, a generative AI tool for automating clinical documentation and billing, according to a press release from the manufacturer. Huma Therapeutics, a UK- and US-based digital healt
- Huma Announces AI Tool to Automate Clinical Notes and Billinghttps://practicaldermatology.com/news/huma-announces-ai-tool-to-automate-clinical-notes-and-billing/2475019/Huma Therapeutics announced the launch Hi Scribe, a generative AI tool for automating clinical documentation and billing, according to a press release from the manufacturer. Huma Therapeutics, a UK- and US-based digital healt
- ZORYVE Foam Cleared by FDA for Full-Body Psoriasishttps://practicaldermatology.com/news/zoryve-foam-cleared-by-fda-for-full-body-psoriasis/2474798/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis in patients aged 12 and older, according to a press release from the manufacturer.
- Analysis Forecasts 140% Rise in Basal Cell Carcinoma by 2050https://practicaldermatology.com/news/analysis-forecasts-140-rise-in-basal-cell-carcinoma-by-2050/2474797/The global burden of skin cancer among adults aged 65 and older has increased steadily over the past three decades and is expected to continue rising through 2050, according to a new analysis of Global Burden of Disease (GBD) Study data.